Surgery & Improved Survival in BRAFV600E Thyroid Cancer with Dr. Dadu

We are honored to have Dr. Ramona Dadu present "Surgery After BRAF Directed Therapy is Associated With Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single Center Retrospective Cohort Study." Dr. Michael Xing joins as the featured expert discussant.

0:00 Webinar

3:21 Dr. Dadu presents

4:04 Progress in Anaplastic Thyroid Carcinoma
Dr. Dadu introduces the progression of anaplastic thyroid carcinoma (ATC) over ten years, highlighting the historical survival patterns of patients. There have been significant survival improvements for ATC patients recently, attributed to new treatment standards, notably BRAF-targeted therapies.

7:10 How Molecular Genetics Impacts Treatment
Dr. Dadu discusses the genesis of ATC from genetic abnormalities, with a 45% frequency of the BRAF mutation in such cancers. Other genetic factors like RAS, TP53, TERTp, and PIK3CA mutations also play crucial roles. This understanding has paved the way for molecular targeted therapies, enhancing the effectiveness of traditional treatments. Clinical trial summaries and a study on the survival benefits of neoadjuvant BRAF-directed therapy prior to surgery are mentioned, showing significant improvements in survival rates.

23:21 Dr. Xing presents

26:20 The BRAF Oncogenic Pathway in Thyroid Cancer
Dr. Xing reviews the role of the BRAF mutation in thyroid cancer, including its prevalence and clinical effects. The mutation's impact on various thyroid cancer types, such as papillary, follicular, anaplastic, and medullary thyroid carcinoma, is detailed.

41:50 The Other Troublemaker in Thyroid Cancer
Dr. Xing focuses on TERT promoter mutations as another significant genetic factor adversely affecting thyroid cancer prognosis. The coexistence and biological significance of TERT and BRAF V600E mutations are discussed, showing the worst clinical outcomes when these mutations are present together. A molecular mechanism involving the FOS-GABP pathway for TERT activation is explained.

52:20 The Relationship of BRAF & TERT Mutations
Dr. Xing emphasizes the necessity of considering BRAF and TERT mutations together for understanding and treating thyroid carcinomas effectively. This approach is vital for developing optimal targeted treatment strategies.

61:01 Discussion with Q&A

** Check out our other programs! **

The THANC Guide
https://thancguide.org/

TIRO: Thyroid Int'l Recommendations Online
https://tiro.expert/

** Follow us on Twitter! **
@thancfoundation - https://shorturl.at/puwS0

THANC on FB - https://shorturl.at/svNY4